2011-08-11
The gold industry standard for risk and cost of drug and vaccine development revisited
Publication
Publication
Vaccine , Volume 29 - Issue 35 p. 5846- 5849
Gold dimensions of pharmaceutical drug development indicate that it takes on average 11.9 years, with an investment around US$ 0.8 Billion, to launch one product on the market. Furthermore, approximately 22% of the drug candidates successfully complete clinical testing. These universally acknowledged proportions largely originate from one single, much cited publication; Dimasi et al. [5]. However an additional six articles describing new chemical entities (NCE) development were identified, which contain little, if any, information on vaccines. Published cumulative success rates range from 7% to 78% and investments calculations span US$ 0.8 to 1.7 Billion. Obviously this disserves further clarification?
| Additional Metadata | |
|---|---|
| , , , , , , | |
| doi.org/10.1016/j.vaccine.2011.06.051, hdl.handle.net/1765/31307 | |
| Vaccine | |
| Organisation | Erasmus Research Institute of Management |
|
Pronker, E., Weenen, T., Commandeur, H., Osterhaus, A., & Claassen, E. (2011). The gold industry standard for risk and cost of drug and vaccine development revisited. Vaccine (Vol. 29, pp. 5846–5849). doi:10.1016/j.vaccine.2011.06.051 |
|